The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: Results from ASCOT

PharmacoEconomics

Volumn 27, Issue 3, 2009, Pages 221-230

  Lindgren, Peter ^a,b,i   Buxton, Martin ^c   Kahan, Thomas ^d   Poulter, Neil R ^e   Dahlöf, Björn ^f   Sever, Peter S ^e   Wedel, Hans ^g   Jönsson, Bengt ^h  

^a i3 Innovus   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BRUNEL UNIVERSITY   (United Kingdom)

^d DANDERYD HOSPITAL   (Sweden)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^h STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

ⁱ NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE PLUS POTASSIUM; DOXAZOSIN; PERINDOPRIL; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEART INFARCTION; HUMAN; HYPERTENSION; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVASCULARIZATION; STROKE; SWEDEN; TREATMENT DURATION; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MODELS, ECONOMIC; PYRROLES; SCANDINAVIA; TREATMENT OUTCOME;

EID: 64749105878     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200927030-00005     Document Type: Article

References (27)

1. O'Brien E. Protocol summary and sub-study protocols. J Hum Hypertension 2001; 15 Suppl. 1: S3-11
2. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 36.1 (9364): 1149-58
3. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofiumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm. (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906
4. Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27 (24): 2982-8
5. Lindgren P, Buxton M, Kahan T, et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil 2005; 12 (1): 29-36
6. Lindgren P, Buxton M, Kahan T, et al. Economic Evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen, is cost-effective compared to an atenolol-based regimen. Heart 2008; 94: e4
7. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13 (4): 322-38
8. The Human Mortality Database [online]. Available from URL: http://www.mortality.org [Accessed 2008 Feb 14]
9. Nordic Centre for Classifications in Health Care. NordDRG users' manual 2006 [online]. Available from URL: http://www.no.rdclass.uu.se/verksam/ norddrgmanual/NordDRG-2006.NC/ [Accessed 2007 Dec 12]
10. UK Statistics Authority. Consumer price indices [online]. Available from URL: http://www.statistics.gov.uk/statbase/Product.asp?vlnk = 868 [Accessed 2007 Dec 12]
11. Statistics Sweden. Konsumentprisindex [online]. Available from URL: http://www.scb.se/Pages/Product-33769.aspx [Accessed 2007 Dec 12]
12. Läkemedelsförmånsnämnden, Guidelines for economic evalution [in Swedish]. Stockholm: Pharmaceutical Benefits Board, 2003
13. Lindgren P, Kahan T, Poulter N, et al. Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy. Eur J Health Econ 2007; 8 (1): 25-30
14. National Health Service. Electronic drug tariff [online]. Available from URL: http://www.nhsbsa.nhs.uk/Prescription Services/924.aspx [Accessed 2007 Nov 25]
15. Pharmaceutical benefits board. Läkemedelp riser 2007 [online]. Available from: http://www.lfn.se [Accessed 2007 Nov 25]
16. Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10 (7): 621-35
17. Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316 (7133): 736-41
18. Lindgren P, Stenestrand U, Hambraeus K, et al. PCI reduces utility loss after MI in Sweden. Eur Heart J 2006; 27 (Suppl. 1): 773
19. National Institute of Clinical Excellence. Guide to the methods of technology appraisal [online]. Available from URL: http://www.nice.org.uk/page. aspx?o=201974 [Accessed 2007 Nov 25]
20. Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman & Hall/CRC, 1993
21. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9 (7): 623-30
22. Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 1997; 17: 382-9
23. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33-64
24. Ekman M, Two essays in health economics: consumption and production by age with emphasis on health care expenditures and economic evaluation of beta-blocker therapy in heart, failure. Stockholm: Stockholm. School of Economics, 2001
25. The Swedish National Board of Health and Welfare's Guidelines for Cardiac Care 2004. Stockholm: The National Board of Health and Welfare, 2004
26. The Australian therapeutic trial in mild hypertension: report by the Management Committee. Lancet 1980; 1 (8181): 1261-7
27. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982; 248 (12): 1465-77